Patriot Financial Group Insurance Agency LLC Acquires 1,254 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Patriot Financial Group Insurance Agency LLC lifted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 17.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,637 shares of the medical research company’s stock after buying an additional 1,254 shares during the period. Patriot Financial Group Insurance Agency LLC’s holdings in IQVIA were worth $1,523,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. American National Bank & Trust bought a new position in shares of IQVIA in the 1st quarter valued at $26,000. ST Germain D J Co. Inc. raised its holdings in IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock valued at $34,000 after buying an additional 76 shares during the last quarter. GKV Capital Management Co. Inc. acquired a new stake in IQVIA during the 4th quarter worth approximately $39,000. Lee Danner & Bass Inc. bought a new stake in IQVIA during the 4th quarter worth approximately $44,000. Finally, Zions Bancorporation N.A. increased its position in IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 85 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. HSBC cut IQVIA from a “buy” rating to a “hold” rating and decreased their price target for the company from $260.00 to $160.00 in a research note on Friday, April 25th. Hsbc Global Res downgraded shares of IQVIA from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 25th. Wall Street Zen cut shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th. Truist Financial decreased their price target on IQVIA from $263.00 to $216.00 and set a “buy” rating for the company in a report on Thursday, April 10th. Finally, Barclays dropped their price objective on IQVIA from $170.00 to $165.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 7th. Eight analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average price target of $226.32.

IQVIA Stock Performance

Shares of IQV stock opened at $152.07 on Monday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a 50-day moving average of $147.69 and a 200-day moving average of $178.90. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88. The company has a market cap of $26.31 billion, a P/E ratio of 20.28, a P/E/G ratio of 1.99 and a beta of 1.28.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.63 by $0.07. The firm had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter last year, the business posted $2.54 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.